• DOI:10.1185/03007995.2012.756393
Corpus ID: 20632486

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

@article{Qi2013PaclitaxelbasedVD,
  title={Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials},
  author={W. Qi and Z. Shen and F. Lin and Y. Sun and Da-liu Min and L. Tang and Ai-na He and Y. Yao},
  journal={Current Medical Research and Opinion},
  year={2013},
  volume={29},
  pages={117 - 125}
}

W. Qi, Z. Shen, +5 authors Y. Yao

Published 2013

Medicine

Current Medical Research and Opinion

Abstract Objectives: Docetaxel and paclitaxel show significant clinical activity in metastatic breast cancer (MBC) and have been approved for MBC by the U.S. Food and Drug Administration, but it is still unclear whether a paclitaxel-based regimen improves outcomes over a docetaxel-based regimen in patients with MBC. We therefore performed a meta-analysis of randomized controlled trials to compare the safety and efficacy of these two regimens in MBC. Methods: We systematically searched for… CONTINUE READING

View on Taylor & Francis

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed